Advertisement
Home 2025

Archives

ASCO: Encorafenib + Cetuximab + Chemo Lengthens Survival in Metastatic CRC

0

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations

ASCO: AI Training Improves Accuracy of HER2 Immunohistochemistry Scoring

0

For HER2 clinical categories, accuracy improved from 66.7 percent without AI to 88.5 percent with AI

ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death

0

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes

ASCO: Alcohol-Associated Cancer Mortality Increased From 1990 to 2021

0

Mortality rates significantly higher in those aged 55 years and older and men in the United States

ASCO: Maintenance Lurbinectedin + Atezolizumab Enhances Survival in Lung Cancer

0

Findings seen for patients with extensive-stage small cell lung cancer, following standard induction therapy

One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years

0

Five-fraction schedule over one week as safe and effective as standard three-week schedule in adjuvant breast radiotherapy

Severe Exacerbations Down With As-Needed Albuterol-Budesonide for Mild Asthma

0

Severe exacerbation occurred in fewer patients receiving albuterol-budesonide versus those receiving albuterol only

Intravenous Tenecteplase Beneficial Before Endovascular Thrombectomy

0

Higher functional independence seen at 90 days for patients with acute ischemic stroke due to large vessel occlusion who present within 4.5 hours

Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss

0

Strong outcomes seen in terms of weight loss, with lower doses of semaglutide used

Trend Toward Survival Benefit Seen for REM-Inhibition in ALS

0

REM inhibition via receipt of antidepressant medications associated with trend toward survival benefit